Compare NTST & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTST | FTRE |
|---|---|---|
| Founded | 2019 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2020 | N/A |
| Metric | NTST | FTRE |
|---|---|---|
| Price | $20.16 | $9.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $20.27 | $15.50 |
| AVG Volume (30 Days) | 1.7M | ★ 1.7M |
| Earning Date | 02-10-2026 | 02-26-2026 |
| Dividend Yield | ★ 4.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | $195,006,000.00 | ★ $2,759,900,000.00 |
| Revenue This Year | $20.93 | $3.21 |
| Revenue Next Year | $10.80 | $0.25 |
| P/E Ratio | $245.16 | ★ N/A |
| Revenue Growth | ★ 19.79 | 1.88 |
| 52 Week Low | $13.74 | $3.97 |
| 52 Week High | $20.25 | $18.67 |
| Indicator | NTST | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 72.52 | 23.01 |
| Support Level | $18.70 | $9.20 |
| Resistance Level | $19.64 | $15.00 |
| Average True Range (ATR) | 0.48 | 1.34 |
| MACD | 0.11 | -0.76 |
| Stochastic Oscillator | 97.94 | 7.19 |
Netstreit Corp is an internally managed real estate investment trust. The company acquires, owns, and manages single-tenant, retail commercial real estate subject to long-term net leases with high-credit quality tenants across the United States. It focuses on tenants in industries where a physical location is critical to the generation of sales and profits, with a focus on necessity goods and essential services in the retail sector, including home improvement, auto parts, drug stores and pharmacies, general retail, grocers, convenience stores, discount stores, and quick-service restaurants. Majorily operates in U.S. States and Other counties, and derives maximum of revenue from USA.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.